Objective
to compare the efficacy of Supreme DES with DP-EES. Supreme DES targets anti proliferative drug delivery of sirolimus (within 4-6 weeks) after which the polymer matrix leaves behind a stent surface with biostable ultra thin coating to facilitate re-endothalisation
Study
prospective multicentre non-inferiority 2:1 randomised study (margin 3.6%)
Population
patients with acute and chronic coronary syndromes
Endpoints
target lesion failure as cardiac death, MI and clinical driven revascularisation at 12 months
Conclusion
Supreme DES implantation among patients with acute and chronic coronary artery syndrome is non-inferior to EES-implantation at 12 months
Lansky et al. Circulation. 2021;143:2143-54
